Heron Therapeutics, Inc. (HRTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.34+4.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Manage legal risks related to Cinvanti patent and court cases: 1 patent loss + 1 delisting notice vs 0 allowed.
Heron aims to grow revenue to about $178 million in 2026. Management targets adjusted EBITDA of $10-$20 million this year. The company focuses on improving operating income despite recent losses. If successful, it could stabilize and grow from current lows.
Heron faces legal challenges that threaten its key drug revenue. Operating income has worsened, showing losses of $4.8 million in Q1 2026. The stock is down 67.5% from its high, reflecting deep market concerns.
The market is selling off sharply, reflecting concerns about legal risks and worsening losses. There is no clear consensus revenue growth priced in, and the stock trades at a very low valuation with negative free cash flow.
Breaks if: Adjusted EBITDA falls below $10 million in FY26
Management targets adjusted EBITDA in the range of $10 million to $20 million for full-year 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. HRTX is currently navigating challenges with its financial performance while operating in a sector that has favorable momentum.
The market seems to have priced in a significant level of uncertainty given HRTX's loss-making status and mixed recent performance. Expectations may be low, especially if guidance is cut or economic conditions worsen.
Management has reaffirmed revenue and EBITDA guidance but later withdrew it due to uncertainties, indicating potential difficulties ahead. The company has shown modest revenue growth, but operating losses persist despite efforts to improve cost management.
The long-term thesis hinges on HRTX's ability to meet its revenue and EBITDA targets, as well as the overall health of the healthcare sector. Key triggers include guidance changes and performance of sector bellwethers that could influence investor sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: New legal rulings cause loss of exclusivity or delisting
Breaks if: Operating income worsens beyond -$4.8 million in next 4 quarters
Focus on improving operating income through revenue growth and cost management.
Stated as a priority in 3 of last 3 quarters. Operating income declined from a small positive $38,000 in 2025-Q4 to losses of $4.8 million in 2026-Q1 and $2.0 million in 2026-Q2. Management emphasized tightening spending and balance sheet reset in 2026-Q2. The trajectory shows operating losses persisting despite cost management efforts, indicating limited progress.
“We reset our balance sheet, tightened our spending, and are considering strategic alternatives.”
“We maintained disciplined cost management and expect temporary gross margin pressure to normalize.”
“Operating income was $38,000 in 2025-Q4 compared to losses in other quarters.”
Breaks if: Revenue falls below $173 million in FY26
Deliver full-year 2026 net revenue in the range of $173 million to $183 million as previously reaffirmed.
Stated as a priority in 2 of last 2 quarters. Management reaffirmed 2026 full-year net revenue guidance of $173 million to $183 million in 2026-Q1 but withdrew guidance in 2026-Q2 due to uncertainty from patent litigation and market conditions. Q1 and Q2 2026 net revenues were $34.7 million and $37.7 million respectively, showing modest growth but below prior expectations. The trajectory is mixed with initial reaffirmation followed by withdrawal reflecting challenges.
“The Company is withdrawing its previously issued full-year 2026 guidance of net product sales and Adjusted EBITDA.”
“The Company reaffirmed full-year 2026 guidance of net revenue of $173 million to $183 million.”
In the next 1 to 3 years, HRTX's trajectory will depend on management execution and external market conditions. Not investment advice.